Trials / Unknown
UnknownNCT04129099
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Hebei Yanda Ludaopei Hospital · Academic / Other
- Sex
- All
- Age
- 2 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 18 subjects to receive GC022F therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GC022F | GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg. |
Timeline
- Start date
- 2019-10-22
- Primary completion
- 2020-09-01
- Completion
- 2022-06-01
- First posted
- 2019-10-16
- Last updated
- 2020-05-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04129099. Inclusion in this directory is not an endorsement.